Skip to content

Study · Systematic review · 2025

11 results

Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.

Nie Y, Zhang Y, Liu B, Meng H

Obesity surgery13 Feb 2025Cited by 15 (Europe PMC)

PMID39948306 (opens in a new tab)DOI10.1007/s11695-025-07733-8 (opens in a new tab)PepBankPUB-39948306
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with suboptimal response or weight regain after bariatric surgery, pooled analysis showed liraglutide produced 9.24% total weight loss after at least 3 months.

    In plain wordsIn people with poor weight loss or weight regain after bariatric surgery, pooled studies linked liraglutide to 9.24% total weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreasePercentage of total weight loss (%TWL)
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    %TWL
    9.24%
    liraglutide

    Source sentences

    Summary
    After at least 3 months of treatment, the pooled %TWL was 9.24% for liraglutide, 11.38% for semaglutide, and 15.50% for tirzepatide, with corresponding weight reductions of 8.56 kg, 11.62 kg, and 12.60 kg, respectively.
    2 context sentences
    Summary · context
    The primary outcomes were percentage of total weight loss (%TWL) and absolute weight loss.
    Summary · context
    Nineteen studies including 1290 patients were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In patients with suboptimal response or weight regain after bariatric surgery, pooled analysis showed liraglutide produced a weight reduction of 8.56 kg after at least 3 months.

    In plain wordsIn people with poor weight loss or weight regain after bariatric surgery, pooled studies linked liraglutide to a weight reduction of 8.56 kg.

    Peptide
    Liraglutide
    Outcome
    DecreaseAbsolute weight loss
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Weight reduction
    8.56 kg
    liraglutide

    Source sentences

    Summary
    After at least 3 months of treatment, the pooled %TWL was 9.24% for liraglutide, 11.38% for semaglutide, and 15.50% for tirzepatide, with corresponding weight reductions of 8.56 kg, 11.62 kg, and 12.60 kg, respectively.
    2 context sentences
    Summary · context
    The primary outcomes were percentage of total weight loss (%TWL) and absolute weight loss.
    Summary · context
    Nineteen studies including 1290 patients were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In patients with suboptimal response or weight regain after bariatric surgery, pooled analysis showed semaglutide produced 11.38% total weight loss after at least 3 months.

    In plain wordsIn people with poor weight loss or weight regain after bariatric surgery, pooled studies linked semaglutide to 11.38% total weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage of total weight loss (%TWL)
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    %TWL
    11.38%
    semaglutide

    Source sentences

    Summary
    After at least 3 months of treatment, the pooled %TWL was 9.24% for liraglutide, 11.38% for semaglutide, and 15.50% for tirzepatide, with corresponding weight reductions of 8.56 kg, 11.62 kg, and 12.60 kg, respectively.
    2 context sentences
    Summary · context
    The primary outcomes were percentage of total weight loss (%TWL) and absolute weight loss.
    Summary · context
    Nineteen studies including 1290 patients were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In patients with suboptimal response or weight regain after bariatric surgery, pooled analysis showed semaglutide produced a weight reduction of 11.62 kg after at least 3 months.

    In plain wordsIn people with poor weight loss or weight regain after bariatric surgery, pooled studies linked semaglutide to a weight reduction of 11.62 kg.

    Peptide
    Semaglutide
    Outcome
    DecreaseAbsolute weight loss
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Weight reduction
    11.62 kg
    semaglutide

    Source sentences

    Summary
    After at least 3 months of treatment, the pooled %TWL was 9.24% for liraglutide, 11.38% for semaglutide, and 15.50% for tirzepatide, with corresponding weight reductions of 8.56 kg, 11.62 kg, and 12.60 kg, respectively.
    2 context sentences
    Summary · context
    The primary outcomes were percentage of total weight loss (%TWL) and absolute weight loss.
    Summary · context
    Nineteen studies including 1290 patients were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In patients with suboptimal response or weight regain after bariatric surgery, pooled analysis showed tirzepatide produced 15.50% total weight loss after at least 3 months.

    In plain wordsIn people with poor weight loss or weight regain after bariatric surgery, pooled studies linked tirzepatide to 15.50% total weight loss.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercentage of total weight loss (%TWL)
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    %TWL
    15.5%
    tirzepatide

    Source sentences

    Summary
    After at least 3 months of treatment, the pooled %TWL was 9.24% for liraglutide, 11.38% for semaglutide, and 15.50% for tirzepatide, with corresponding weight reductions of 8.56 kg, 11.62 kg, and 12.60 kg, respectively.
    2 context sentences
    Summary · context
    The primary outcomes were percentage of total weight loss (%TWL) and absolute weight loss.
    Summary · context
    Nineteen studies including 1290 patients were included.
  6. 06HumanSystematic reviewEfficacy outcome

    In patients with suboptimal response or weight regain after bariatric surgery, pooled analysis showed tirzepatide produced a weight reduction of 12.60 kg after at least 3 months.

    In plain wordsIn people with poor weight loss or weight regain after bariatric surgery, pooled studies linked tirzepatide to a weight reduction of 12.60 kg.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAbsolute weight loss
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Weight reduction
    12.6 kg
    tirzepatide

    Source sentences

    Summary
    After at least 3 months of treatment, the pooled %TWL was 9.24% for liraglutide, 11.38% for semaglutide, and 15.50% for tirzepatide, with corresponding weight reductions of 8.56 kg, 11.62 kg, and 12.60 kg, respectively.
    2 context sentences
    Summary · context
    The primary outcomes were percentage of total weight loss (%TWL) and absolute weight loss.
    Summary · context
    Nineteen studies including 1290 patients were included.
  7. 07HumanSystematic reviewEfficacy outcome

    In patients after bariatric surgery, pooled analysis showed liraglutide for 6 months or less gave 7.65% total weight loss and 7.47 kg weight reduction.

    In plain wordsAfter bariatric surgery, pooled studies linked liraglutide used for 6 months or less to 7.65% total weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss (%TWL and kg) at 6 months or less
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 months or lessAs given in this study (human).

    Measurements

    %TWL
    7.65%
    liraglutide, ≤ 6 months
    Weight loss
    7.47 kg
    liraglutide, ≤ 6 months

    Source sentences

    Summary
    Additionally, %TWL and weight loss with liraglutide use were 7.65% and 7.47 kg for ≤ 6 months, 10.22% and 9.30 kg for 6-12 months, and 10.80% and 9.72 kg for ≥ 12 months.
    2 context sentences
    Summary · context
    The primary outcomes were percentage of total weight loss (%TWL) and absolute weight loss.
    Summary · context
    Nineteen studies including 1290 patients were included.
  8. 08HumanSystematic reviewEfficacy outcome

    In patients after bariatric surgery, pooled analysis showed liraglutide for 6-12 months gave 10.22% total weight loss and 9.30 kg weight reduction.

    In plain wordsAfter bariatric surgery, pooled studies linked liraglutide used for 6-12 months to 10.22% total weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss (%TWL and kg) at 6-12 months
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6-12 monthsAs given in this study (human).

    Measurements

    %TWL
    10.22%
    liraglutide, 6-12 months
    Weight loss
    9.3 kg
    liraglutide, 6-12 months

    Source sentences

    Summary
    Additionally, %TWL and weight loss with liraglutide use were 7.65% and 7.47 kg for ≤ 6 months, 10.22% and 9.30 kg for 6-12 months, and 10.80% and 9.72 kg for ≥ 12 months.
    2 context sentences
    Summary · context
    The primary outcomes were percentage of total weight loss (%TWL) and absolute weight loss.
    Summary · context
    Nineteen studies including 1290 patients were included.
  9. 09HumanSystematic reviewEfficacy outcome

    In patients after bariatric surgery, pooled analysis showed liraglutide for 12 months or more gave 10.80% total weight loss and 9.72 kg weight reduction.

    In plain wordsAfter bariatric surgery, pooled studies linked liraglutide used for 12 months or more to 10.80% total weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss (%TWL and kg) at 12 months or more
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 months or moreAs given in this study (human).

    Measurements

    %TWL
    10.8%
    liraglutide, ≥ 12 months
    Weight loss
    9.72 kg
    liraglutide, ≥ 12 months

    Source sentences

    Summary
    Additionally, %TWL and weight loss with liraglutide use were 7.65% and 7.47 kg for ≤ 6 months, 10.22% and 9.30 kg for 6-12 months, and 10.80% and 9.72 kg for ≥ 12 months.
    2 context sentences
    Summary · context
    The primary outcomes were percentage of total weight loss (%TWL) and absolute weight loss.
    Summary · context
    Nineteen studies including 1290 patients were included.
  10. 10HumanSystematic reviewEfficacy outcome

    In patients after bariatric surgery, pooled analysis showed semaglutide gave 10.18% total weight loss and 9.43 kg weight reduction at 6 months.

    In plain wordsAfter bariatric surgery, pooled studies linked semaglutide to 10.18% total weight loss at 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss (%TWL and kg) at 6 months
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    %TWL
    10.18%
    semaglutide, 6 months
    Weight reduction
    9.43 kg
    semaglutide, 6 months

    Source sentences

    Summary
    For semaglutide, the %TWL and weight reduction were 10.18% and 9.43 kg at 6 months, and 13.15% and 14.68 kg at 12 months.
    2 context sentences
    Summary · context
    The primary outcomes were percentage of total weight loss (%TWL) and absolute weight loss.
    Summary · context
    Nineteen studies including 1290 patients were included.
  11. 11HumanSystematic reviewEfficacy outcome

    In patients after bariatric surgery, pooled analysis showed semaglutide gave 13.15% total weight loss and 14.68 kg weight reduction at 12 months.

    In plain wordsAfter bariatric surgery, pooled studies linked semaglutide to 13.15% total weight loss at 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss (%TWL and kg) at 12 months
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    %TWL
    13.15%
    semaglutide, 12 months
    Weight reduction
    14.68 kg
    semaglutide, 12 months

    Source sentences

    Summary
    For semaglutide, the %TWL and weight reduction were 10.18% and 9.43 kg at 6 months, and 13.15% and 14.68 kg at 12 months.
    2 context sentences
    Summary · context
    The primary outcomes were percentage of total weight loss (%TWL) and absolute weight loss.
    Summary · context
    Nineteen studies including 1290 patients were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.